GMP Certification Differences Among Major US Cord Blood Banks

GMP certification differences among US cord blood banks reflect a layered system. FDA registration establishes the mandatory floor, while accreditation, state licensing, and biologics licensure impose different requirements above it. The meaningful comparison is therefore not whether a bank claims “GMP compliance,” but which standards apply to its work and what its credentials demonstrate.

Why "GMP certified" tells families almost nothing about a cord blood bank's actual quality

A parent comparing two banks’ marketing sheets may find that both claim “GMP compliance,” yet learn little about how their standards differ. No single US body issues a uniform cord blood banking credential called “GMP certified.” Instead, the phrase compresses several separate requirements and voluntary accreditations into one apparent assurance. Those layers measure different things, so the shared wording can conceal important distinctions.

This affects both families choosing storage and clinicians choosing a unit for transplant, though each may need different evidence for how they plan to use it. Cord for Life, which banks cord blood and placentas and describes a commitment to empowering birth, provides families and clinicians with credentials spanning federal registration, voluntary accreditation, and state licensing to assess. Reading that combination requires separating a bank’s legal obligations from the additional standards it chooses to meet.

FDA registration as the mandatory floor and what it does not establish

FDA registration starts with establishment registration and listing under the agency’s rules for human cells, tissues, and cellular and tissue-based products (HCT/P). It is the non-negotiable starting point for all US cord blood banks. The applicable baseline includes donor screening, infectious disease testing, labeling, and reporting requirements. It also requires compliance with current good tissue practice (cGTP), which is distinct from current good manufacturing practice (cGMP).

FDA conducts surprise inspections of registered facilities, making compliance a continuous obligation. However, a requirement shared by every bank cannot, by itself, distinguish the quality standards of one compliant bank from another. Registration alone does not show that a bank has BLA approval or meets all cGMP drug-manufacturing requirements.

The regulatory fork between private and public banks, and where cGMP actually enters

Cord blood stored for use by the donor or first- or second-degree relatives does not require FDA approval before use. For these private-bank uses, cGTP is the operative FDA standard. The distinction concerns the intended use of the product.

Cord blood intended for unrelated patients meets the statutory definition of a “drug” under the Food, Drug and Cosmetic Act and a “biological product” under Section 351 of the Public Health Service Act. It must be licensed under a Biologics License Application (BLA) or proceed under an Investigational New Drug Application (IND). The BLA requirement is where full cGMP discipline becomes legally mandatory. That requirement became effective in October 2011, but not all US public banks have completed the difficult and expensive licensure process.

Banks moving toward licensure may operate in a transitional status, and BLA approval does not retroactively license their inventory. Only new incoming collections are covered when a bank receives its license, while older inventory remains unlicensed. The manufacturing model is also hard to apply because each cord blood collection is a separate batch, which differs from how conventional pharmaceutical manufacturing works. That imperfect fit helps explain the importance of voluntary standards designed around cord blood banking itself.

What AABB accreditation covers and where it deliberately leaves room for variation

AABB accreditation covers cord blood banks and many other facilities that work with cellular therapy and blood products. Its breadth is a design choice, supported by a complete quality system that covers maternal screening and testing, processing, storage, and patient outcomes. A committee of cord blood professionals, an ethicist, and stem cell transplant physicians revises the standards every two years. Accreditation is granted for two years, after which banks reapply, and applicants must have operated for at least six months.

CMS has granted AABB “deemed status” as an accrediting organization under CLIA. The International Society for Quality in Health Care (ISQua) also accredits the AABB accreditation program itself. These recognitions establish the standing of the program without making its requirements identical to those of FACT. AABB’s approach emphasizes quality essentials that can apply across different cellular products.

AABB requires traceability to a donor or source but does not mandate linkage of the cord blood unit to the infant donor. It requires an emergency plan for storage and transport continuity, rather than specifying continuous safe storage and transport. AABB’s Standards for Cellular Therapy Services require records to be retained for at least 10 years from creation or final disposition of the product. Its standards do not specify transport timing, although the FDA recommends a 48-hour window.

What FACT accreditation adds, and why transplant centers treat it as a selection criterion

FACT’s cord-blood-specific standards make several of those discretionary matters explicit. They require specific characterization and validation for CD34+ and CD45+ cell viability. They also require reporting of data to cord blood registries. For allogeneic products, FACT requires validation that donor and recipient are different individuals when there is a complete HLA match. These provisions make the standard particularly relevant to the identity and characterization of units considered for transplantation.

FACT also requires safe storage and transport at all times and requires banks to keep records indefinitely. Its transport window is 48 hours for public donations, aligned with the FDA recommendation, and 72 hours for family banks. Leading transplant and cancer centers use FACT standards when selecting units from public inventory. Consequently, the distinction from AABB is not merely a difference in accreditation language but one that can affect clinical selection.

Access to FACT accreditation also has a higher entry barrier. Its minimum inventory threshold and much higher one-time application fee help explain why smaller or newer banks may have AABB alone. A missing FACT credential therefore indicates only the absence of demonstrated compliance through that particular cord-blood-specific accreditation.

State licensing as a mandatory GMP-adjacent layer that most families overlook

State licensing operates in parallel with federal registration and voluntary accreditation. In states that require it, the relevant license constitutes a separate, binding quality layer, regardless of which voluntary credentials the bank holds. New York’s quality floor exceeds what FDA registration alone requires, making state licensure a meaningful point of comparison.

California’s reach extends beyond facilities physically located in the state. It requires a California Biologics License for banks that collect, process, store, or distribute cord blood within California, control those functions there, accept California collections, or release stored cord blood to California. The state has adopted AABB Cellular Therapy Standards into its Health and Safety Code. Thus, standards associated with a voluntary accreditation can also become part of a mandatory legal requirement.

New Jersey and Maryland also have state licensing requirements. New York and California licenses add mandatory inspection and testing layers that federal registration alone does not describe. The consequence for credential reading is straightforward, because a bank’s location is not the only relevant fact. Where it accepts collections and where it releases stored cord blood can also determine which state obligations apply.

How the layers combine in practice when reading a real bank's credentials

Cord for Life operates as both a public and private bank. It holds FDA registration, AABB accreditation, and AABB Cellular Starting Material (CSM) Qualification. It also holds state licenses in New York, California, New Jersey, and Maryland, with collection approvals in Delaware and Illinois. Cord for Life follows the standards of the National Marrow Donor Program.

Cord Blood Registry (CBR), in San Bruno, CA, is the largest private bank in the US by stored units. It holds FDA registration, CLIA certification, AABB accreditation, and ISO 9001:2015 certification, with the longest continuous AABB accreditation history among private banks. AlphaCord, in Atlanta, GA, holds FDA registration and AABB accreditation through the CryoPoint Biorepository in Brownsburg, Indiana. FACT accreditation is not noted in the supplied credential information for AlphaCord.

The public-bank picture adds another dimension. The five HRSA-contracted banks named here are Bloodworks Northwest, Carolinas Cord Blood Bank at Duke, Cleveland Cord Blood Center, LifeSouth, and MD Anderson Cord Blood Bank. HRSA prioritizes BLA holders with demonstrated capability to bank genetically varied units, placing that combination in the most regulated tier. However, a bank-level credential still has to be read in light of the intended unit and its licensing status. General quality-system or laboratory credentials, including ISO 9001 and CAP, add to what cord-blood-specific accreditation covers but cannot take its place.

The legitimate case for AABB-only accreditation, and where it falls short for allogeneic use

AABB-only accreditation is not evidence that a bank necessarily operates at lower quality. AABB’s systems-based approach is intended to be flexible across cellular product types and more amenable to innovation than a cord-blood-specific checklist. It remains a genuine, inspected quality credential. The strongest case for that approach concerns private storage for personal family use, where the probability of allogeneic transplant use is very low. For that use, a broader quality system may meet the needs of the service without FACT accreditation.

The argument becomes less sufficient when a unit may be needed by an unrelated patient or released to a transplant center. FACT’s requirements for CD34+ and CD45+ characterization, storage continuity, indefinite records, and donor-recipient validation then become clinically relevant. A bank may have strong internal practices, but those practices do not themselves establish FACT accreditation. Leading transplant centers use FACT standards to choose units, so they may be less willing to accept units from a bank without that credential.

How to evaluate a US cord blood bank's credentials before making a decision

The first step is to confirm that the bank appears on the FDA’s establishment registration list. If it does not, do not proceed. Next, check the AABB accredited facilities list and the FACT-accredited bank list themselves, without relying on what the bank says in its marketing copy. This separates a bank’s description of its quality system from its documented accreditation. It also makes clear whether cord-blood-specific FACT standards form part of the credential profile.

Then confirm the relevant state licenses if the bank operates in or accepts collections from New York or California. New York’s inspections add a check on whether the bank meets its standards. For units from public banks that will be used for transplant, check the bank’s BLA status and HRSA contract status. The five HRSA-contracted banks represent the most rigorously regulated public inventory, but BLA approval must still be interpreted correctly for older collections. A public bank unable to explain its BLA status or movement toward licensure leaves an important question unresolved.

FDA registration, AABB and FACT accreditation, and relevant state licenses represent the most complete private-bank credential profile described here. FDA registration with AABB alone is a narrower profile, but not a disqualifying one for purely personal family use. An unexplained “GMP certified” claim, or reliance on ISO 9001 or CLIA as the primary quality credential without AABB or FACT, deserves scrutiny. Families and clinicians who can read these layers are better positioned to choose a bank on the standards that matter to their decision.